Patients undergoing bisphosphonate treatments – particularly intravenous – are at risk of developing a potentially debilitating condition called MRONJ – or Medication-Related Osteonecrosis of the Jaw.

The risk is felt to be in the order of 0.01 to 0.1% for oral bisphonate treatments and much higher at 0.8 to 12% for Intravenous therapy. This can result in sections of the jaw dying off and in severe cases requires reconstruction.

The team at H+N SL have extensive experience in managing patients with this condition.